JPRN-jRCT2051210053已完成1 期
An open label dose escalation study to investigate the safety and tolerability of boron neutron capture therapy (BNCT) with SPM-011 and BNCT treatment system (BNCT30) in patients with recurrent malignant glioma (WHO grade III and grade IV)
Miyatake Shin-ichi0 个研究点目标入组 9 人开始时间: 2021年7月16日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 9
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 < 75age old（—）
- 性别
- All
入选标准
- •1. Karnofsky performance status >= 60
- •2. Patients with recurrent malignant glioma confirmed by imaging or histological diagnosis with previous radiotherapy to the target lesion.
- •3. Patients who have received 50 Gy to 65 Gy of prior radiation therapy to the target lesion and more than 180 days have passed since the last irradiation.
排除标准
- •1. Patients with active multiple primary cancers
- •2. Patients with meningeal dissemination or two or more discontinuous tumor lesions
- •3. Patients who are using steroids other than for the treatment of cerebral edema or who have complications requiring systemic administration of steroids
研究者
相似试验
进行中（未招募）
1 期
An Open-Label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular AtrophySpinal Muscular Atrophy (SMA)EUCTR2017-000327-27-Outside-EU/EEAIonis Pharmaceuticals, Inc.34
进行中（未招募）
1 期
Study to test a new drug to treat patients with Pulmonary Arterial Hypertension (PAH).Pulmonary arterial hypertensionEUCTR2017-000212-41-ESGlaxoSmithKline, S.A.24
进行中（未招募）
1 期
Study to test a new drug to treat patients with Pulmonary Arterial Hypertension (PAH)MedDRA version: 20.0Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 20.0Level: LLTClassification code 10077739Term: Pulmonary arterial hypertension WHO functional class ISystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 20.0Level: LLTClassification code 10077729Term: Pulmonary arterial hypertension WHO functional class IIISystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 20.0Level: LLTClassification code 10077740Term: Pulmonary arterial hypertension WHO functional class IISystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersPulmonary arterial hypertensionEUCTR2017-000212-41-DEGlaxoSmithKline Research & Development Ltd23
已完成
1 期
An interventional study to evaluate the safety, tolerability (how well a substance is tolerated by participants), and Pharmacokinetics (PK, the measure of how the human body processes a substance), of different dosages of TTI-0102 when given to healthy participants as either a single oral dose, or as an oral dose give twice daily on one day (as a potential treatment for COVID-19), compared with a single oral dose of the marketed product Cystagon (registered trademark).ACTRN12621000131853Thiogenesis Therapeutics, Inc.12
已完成
1 期
SUBurothelial DUrvalumab injEction-1 (SUBDUE-1)Muscle invasive or high risk non muscle invasive bladder cancerCancer - BladderACTRN12620000063910South Metropolitan Health Service11